Answers are grounded in this paper and cite their sources.
Case-control study reveals elevated estradiol 16α-hydroxylation in systemic lupus erythematosus, suggesting potent estrogenic metabolites contribute to disease pathogenesis.
Systemic lupus erythematosus (SLE) is one of many chronic diseases with a predilection for the human female. The reasons for the high female to male (9:1) incidence remain unknown. The total extent of hydroxylation estradiol at either C-16 to more estrogenic metabolites or at C-2 to the catechol estrogens was determined by a radiometric method in the human. Comparing 23 SLE patients to 44 normal controls, an increase in the extent of hydroxylation toward the 16 alpha-metabolites was found in SLE (SLE 15.2 +/- 4.3%, range 8.8-30%; normal 9.1 +/- 2.3%, range 5.3-14.4%; P less than 0.001). Increased 16 alpha-hydroxylation was found in both males (SLE 13.2 +/- 3.0%, normal 8.3 +/- 2.1%) and females (SLE 15.7 +/- 5%, normal 9.9 +/- 2.2%) with disease when compared to normal subjects. In addition, studies of several other chronic diseases by the same method did not indicate a similar alteration in 16 hydroxylation. No change in hydroxylation at C-2 was found in male patients, but a decrease was found in female patients. These data suggest that increased hydroxylation of estradiol at C-16 occurs in SLE. The 16 alpha-metabolites have been shown to be potent estrogens, and these data might give some insight into the pathogenesis of the disease.
No takes yet. Share an insight, caveat, or question.
Lahita et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: